Children's Cancer Therapy Development Institute

For many forms of childhood cancer, we’ve seen little to no advancement in treatment options for over thirty years. To overcome this stalemate, cc-TDI is embarking upon a bold scientific course of discovery to create more effective clinical trials for those childhood cancers that are most in need of treatments to save kids’ lives. Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer. By proving these methods in the laboratory, we can deliver smart, hope-filled discoveries to be prioritized in clinical trials for kids. Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our lab nestled between the medical center and the Silicon Forest.

Enventure

Enventure is growing Houston's life science innovation community. Our programming empowers students and aspiring entrepreneurs to engage the startup community and launch their own startups. To support our vision of a thriving life science startup community, we build programs that bridge the institutions of the Texas Medical Center (the largest medical center in the world) & the Greater Houston community. These programs connect students & professionals in fields including (but not limited to) the life sciences, medicine, business, engineering, and computer science. Our grassroots non-profit organization is free + open, healthcare focused, and community driven.

Akrevia Therapeutics, Inc.

Akrevia Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics. The company’s proprietary Aklusion™ platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of natural immune-activating proteins that can be safely delivered. Akrevia is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer. To learn more, please visit www.akrevia.com. The company is financed by blue chip investors F-Prime Capital Partners and Atlas Venture. Akrevia has licensed key technology from Thomas Jefferson University and City of Hope. The company is located in Cambridge, Massachusetts.

Epiodyne

Epiodyne was founded to develop breakthrough small molecule medicines based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke. Together with our founders and with the highly experienced medicinal chemistry team at R2M Pharma (https://www.linkedin.com/company/r2m-pharma/), we are using quantitative pharmacological and behavioral techniques to translate our insights into novel medicines for patients with opioid use disorder (OUD). We are backed by a syndicate of experienced biotech VCs and located in the Bay Area.

Executive Mindshare

Executive Mindshare is a Social Media Network for industry verticals. Executive Mindshare is designed for a global audience of senior business professionals, policy makers, thought leaders and financial decision-makers in specific vertical business industries. Developed to build the industry influence of business executives, Executive Mindshare delivers relevant and targeted news content, user content and access to a vibrant social network of industry leaders and opinion leaders.